An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

Phosplatin Therapeutics is harnessing immunogenic cell death (ICD) as an alternative mechanism to existing cancer immunotherapy strategies. PT-112, Phosplatin’s lead ICD inducer, is in phase 2 ...

“These data demonstrate that our first-in-human vaccine based on our PlaCCine platform is safe and immunogenic and is well-suited to developing vaccine candidates for protecting the population ...

Harnessing immunogenic cell death (ICD)—an immunostimulatory form of cancer cell death in the tumor microenvironment—to help activate a patient’s immunity and trigger a tumor-specific immune ...

In addition, they can activate an abscopal effect, inducing immunogenic cell death and stimulating an antitumor immune ...

Get Instant Summarized Text (Gist) A self-assembling nanoplatform has been developed to enhance cancer photoimmunotherapy by targeting tumor cells and inducing immunogenic cell death through ...

Imunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN-101 DNA plasmid vaccine. The investigational vaccine, based on the ...

Therefore, it is desirable to perform more extensive histocompatibility testing for the most immunogenic organs, but the length of cold ischemia time an organ will tolerate limits the extent of ...

Imunon CEO and president Stacy Lindborg said: “These data demonstrate that our first-in-human vaccine based on our PlaCCine platform is safe and immunogenic and is well-suited to developing ...